Metagenomi, Inc. Common Stock
MGXNASDAQHealthcare● Active
$1.29
+$0.01(+0.78%)
Market Cap$48564449
P/E Ratio—
52W High$3.95
52W Low$1.24
Metagenomi, Inc. Common Stock (MGX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MGX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $25.21M | $52.30M | $44.76M | $17.20M | $0.24M |
| Cost of Revenue | $5.32M | $0.00M | $94.40M | $1.73M | $0.39M |
| Gross Profit | $19.89M | $52.30M | ($49.65M) | $15.47M | ($0.14M) |
| Gross Margin %(computed) | 78.91% | 100.00% | -110.93% | 89.92% | -59.26% |
| Operating Expenses | |||||
| R&D Expenses | $94.43M | $109.18M | $94.40M | $43.14M | $14.48M |
| G&A Expenses | $26.79M | $32.02M | $28.84M | $18.70M | $9.71M |
| Total Operating Expenses | $115.91M | $141.20M | $28.84M | $60.11M | $23.80M |
| Operating Income | ($96.01M) | ($88.90M) | ($78.49M) | ($44.64M) | ($23.95M) |
| Operating Margin %(computed) | -380.85% | -170.00% | -175.38% | -259.53% | — |
| Interest Income | $9.47M | $14.72M | $15.47M | $3.42M | $0.04M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.10M | $0.30M |
| Income Before Tax | ($87.93M) | ($83.57M) | ($60.23M) | ($41.02M) | ($21.44M) |
| Income Tax Expense | ($0.06M) | ($5.51M) | $8.03M | $2.57M | $0.00M |
| Net Income | ($87.87M) | ($78.06M) | ($68.25M) | ($43.59M) | ($21.44M) |
| Net Margin %(computed) | -348.54% | -149.26% | -152.50% | -253.45% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.36 | $-2.09 | $-1.82 | $-1.16 | $-3.62 |
| Wtd Avg Shares | 37.25M | 37.42M | 37.47M | 37.47M | 5.93M |
| EBITDA | ($90.70M) | ($83.49M) | ($74.28M) | ($39.19M) | ($20.75M) |
| EBITDA Margin %(computed) | -359.76% | -159.66% | -165.98% | -227.87% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Metagenomi, Inc. Common Stock data
About Metagenomi, Inc. Common Stock (MGX) Income Statement
Metagenomi, Inc. Common Stock (MGX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MGX reported revenue of $0.03B, gross profit of $0.02B (gross margin 78.91%), and net income of ($0.09B) — a net profit margin of -348.54%.
Frequently asked questions
MGX · 4 questionsMetagenomi, Inc. Common Stock (MGX) reported revenue of $0.03B for 2025, down 51.8% year-over-year.
MGX revenueMGX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09